One of the most vivid metaphors for chemotherapy is that of a bomb: it obliterates both good and bad cells, with the hope that only the good ones regenerate. While traditional chemotherapy remains a significant tool in cancer treatment, there’s been a recent shift towards more precise therapies that selectively target cancer cells. In the context of urothelial (or bladder) cancer, this shift is unfolding in real-time. The findings from the EV 103 study introduce a groundbreaking approach to combating this disease, bypassing the need for conventional chemotherapy.
Despite its continued role in urothelial cancer treatment, not every patient is an ideal candidate for chemotherapy due to its potential side effects often outweighing the benefits. Historically, options outside of chemotherapy have been limited. One notable alternative is a drug called Pembrolizumab, an immune therapy that empowers the body’s own immune cells to better locate and attack cancer cells. Although available for bladder cancer, many patients haven’t experienced significant or enduring responses to this agent.
Another promising option in urothelial cancer treatment is Enfortumab vedotin (trade name: Padcev). Enfortumab vedotin delivers a cancer-killing agent directly to cancer cells while sparing most healthy cells. It achieves this by targeting a receptor called Nectin 4. Upon binding to Nectin 4, the compound releases the segment that specifically eradicates the cancer cells within the tumor.
In the EV103 clinical trial, patients who were ineligible for chemotherapy due to specific reasons received a combination of both Pembrolizumab and Enfortumab vedotin. The outcomes were nothing short of remarkable. Nearly 70% of individuals experienced tumor shrinkage, with tumors often vanishing completely. Responding patients exhibited the potential for sustained response durations. While certain adverse effects require monitoring, there were no unexpected toxicities arising from the combination of these agents.
EV103 provides compelling evidence that combination therapy could spearhead a move away from chemotherapy for individuals with advanced urothelial cancers. Further studies are underway to corroborate these advantages, fostering a sense of optimism regarding the future potential of these therapeutic agents.
About the author
Dr. Landau’s influence extends to medical education, where he has passionately nurtured the growth of future oncologists, imparting not only knowledge but also compassion. His commitment to illuminating the path of medical students, residents, and fellows ensures that the legacy of expertise and empathy endures. As a valued contributor to MedOncMD, Dr. Landau eagerly anticipates sharing insights, knowledge, and novel perspectives. His presence embodies the platform’s dedication to offering information that transcends the ordinary doctor-patient discourse.
Engage with Dr. Landau’s expertise and ignite your curiosity on “Ask MedOnCMD” as he invites you to explore the vast landscape of oncology with a fresh outlook.